A strategic agreement between Bristol Myers Squibb (BMS) and Hengrui Pharma expands China’s role in early-stage drug development, covering 13 oncology, hematology, and immunology programs with up to $15.2 billion in potential value. Announced in 2026, the deal accelerates clinical
